These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

393 related items for PubMed ID: 8878606

  • 1. Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci.
    Nicas TI, Mullen DL, Flokowitsch JE, Preston DA, Snyder NJ, Zweifel MJ, Wilkie SC, Rodriguez MJ, Thompson RC, Cooper RD.
    Antimicrob Agents Chemother; 1996 Sep; 40(9):2194-9. PubMed ID: 8878606
    [Abstract] [Full Text] [Related]

  • 2. Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria.
    Nicas TI, Mullen DL, Flokowitsch JE, Preston DA, Snyder NJ, Stratford RE, Cooper RD.
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2585-7. PubMed ID: 8585753
    [Abstract] [Full Text] [Related]

  • 3. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.
    Biavasco F, Vignaroli C, Lupidi R, Manso E, Facinelli B, Varaldo PE.
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2165-72. PubMed ID: 9333042
    [Abstract] [Full Text] [Related]

  • 4. European Glycopeptide Susceptibility Survey of gram-positive bacteria for 1995. European Glycopeptide Resistance Survey Study Group.
    Felmingham D, Brown DF, Soussy CJ.
    Diagn Microbiol Infect Dis; 1998 Aug; 31(4):563-71. PubMed ID: 9764397
    [Abstract] [Full Text] [Related]

  • 5. In vitro activity of LY264826, a new glycopeptide antibiotic, against gram-positive bacteria isolated from patients with cancer.
    Rolston KV, Nguyen H, Messer M.
    Antimicrob Agents Chemother; 1990 Nov; 34(11):2137-41. PubMed ID: 2149921
    [Abstract] [Full Text] [Related]

  • 6. In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae.
    Patel R, Rouse MS, Piper KE, Cockerill FR, Steckelberg JM.
    Diagn Microbiol Infect Dis; 1998 Feb; 30(2):89-92. PubMed ID: 9554174
    [Abstract] [Full Text] [Related]

  • 7. [In vitro activity of vancomycin and teicoplanin against gram-positive cocci].
    Bezian MC, Ribou G, Masquelier B.
    Pathol Biol (Paris); 1992 May; 40(5):461-5. PubMed ID: 1386667
    [Abstract] [Full Text] [Related]

  • 8. In vitro activities of two ketolides, HMR 3647 and HMR 3004, against gram-positive bacteria.
    Malathum K, Coque TM, Singh KV, Murray BE.
    Antimicrob Agents Chemother; 1999 Apr; 43(4):930-6. PubMed ID: 10103202
    [Abstract] [Full Text] [Related]

  • 9. In vitro activity of LY264826 compared to other glycopeptides and daptomycin.
    Chin NX, Neu HC.
    Diagn Microbiol Infect Dis; 1991 Apr; 14(2):181-4. PubMed ID: 1651826
    [Abstract] [Full Text] [Related]

  • 10. Multidrug-resistant gram-positive pathogens. An update on current microbiological patterns.
    Marchese A, Debbia EA, Bacca D, Balistreri G, Musolino B, Schito GC.
    Drugs; 1997 Apr; 54 Suppl 6():11-20. PubMed ID: 9474477
    [Abstract] [Full Text] [Related]

  • 11. New semisynthetic glycopeptides MDL 63,246 and MDL 63,042, and other amide derivatives of antibiotic A-40,926 active against highly glycopeptide-resistant VanA enterococci.
    Malabarba A, Ciabatti R, Scotti R, Goldstein BP, Ferrari P, Kurz M, Andreini BP, Denaro M.
    J Antibiot (Tokyo); 1995 Aug; 48(8):869-83. PubMed ID: 7592033
    [Abstract] [Full Text] [Related]

  • 12. In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci.
    Schwalbe RS, McIntosh AC, Qaiyumi S, Johnson JA, Johnson RJ, Furness KM, Holloway WJ, Steele-Moore L.
    Antimicrob Agents Chemother; 1996 Oct; 40(10):2416-9. PubMed ID: 8891155
    [Abstract] [Full Text] [Related]

  • 13. Intracellular activity of vancomycin and Ly333328, a new semisynthetic glycopeptide, against methicillin-resistant Staphylococcus aureus.
    al-Nawas B, Shah PM.
    Infection; 1998 Oct; 26(3):165-7. PubMed ID: 9646108
    [Abstract] [Full Text] [Related]

  • 14. Novel glycopeptide antibiotics: N-alkylated derivatives active against vancomycin-resistant enterococci.
    Rodriguez MJ, Snyder NJ, Zweifel MJ, Wilkie SC, Stack DR, Cooper RD, Nicas TI, Mullen DL, Butler TF, Thompson RC.
    J Antibiot (Tokyo); 1998 Jun; 51(6):560-9. PubMed ID: 9711219
    [Abstract] [Full Text] [Related]

  • 15. Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant gram-positive organisms.
    Fraise AP, Andrews J, Wise R.
    J Antimicrob Chemother; 1997 Sep; 40(3):423-5. PubMed ID: 9338497
    [Abstract] [Full Text] [Related]

  • 16. In vitro activity of the new glycopeptide decaplanin.
    Neu HC, Chin NX, Niu WW.
    Eur J Clin Microbiol Infect Dis; 1992 May; 11(5):458-62. PubMed ID: 1330562
    [Abstract] [Full Text] [Related]

  • 17. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
    McKay GA, Beaulieu S, Arhin FF, Belley A, Sarmiento I, Parr T, Moeck G.
    J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
    [Abstract] [Full Text] [Related]

  • 18. Proficiency of Italian clinical laboratories in detecting reduced glycopeptide susceptibility in Enterococcus and Staphylococcus spp. using routine laboratory methodologies.
    Jones ME, Gesu G, Ortisi G, Sahm DF, Critchley IA, Goglio A, Associazione Microbiologi Clinici Italiani (AMCLI) Committee for Antibiotics.
    Clin Microbiol Infect; 2002 Feb; 8(2):101-11. PubMed ID: 11952723
    [Abstract] [Full Text] [Related]

  • 19. Glycopeptide carboxamides active against vancomycin-resistant enterococci.
    Zweifel MJ, Snyder NJ, Cooper RD, Nicas TI, Mullen DL, Butler TF, Rodriguez MJ.
    J Antibiot (Tokyo); 2003 Mar; 56(3):289-95. PubMed ID: 12760685
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin.
    Harland S, Tebbs SE, Elliott TS.
    J Antimicrob Chemother; 1998 Feb; 41(2):273-6. PubMed ID: 9533471
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.